STOCK TITAN

ImmunityBio (IBRX) Stock News

IBRX NASDAQ

ImmunityBio, Inc. reports developments as a commercial-stage biotechnology company focused on immunotherapies designed to activate innate and adaptive immune responses for cancer and infectious disease. Its news centers on ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used with BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.

Recurring updates cover ANKTIVA product revenue and unit demand, global regulatory authorizations and commercial availability, distribution partnerships, and scientific presentations involving bladder cancer, lung cancer, and broader IL-15 oncology programs. Company announcements also address BCG-naïve NMIBC clinical development, FDA promotional-compliance correspondence, and financing arrangements tied to revenue interests and convertible debt.

Rhea-AI Summary

ImmunityBio (IBRX) announced survey findings showing 53% of military service members and veterans surveyed with bladder cancer were diagnosed by age 50. The Harris Poll surveyed 100 U.S. adults with non-muscle invasive bladder cancer (NMIBC), cancer that has not invaded the bladder muscle, online during October 9–21, 2026.

63% reported treatment barriers or challenges, including long waits (35%) and difficulty coordinating VA and non-VA care (27%). Challenges accessing provider-recommended treatment affected 49%, while 44% reported a long wait to begin treatment after diagnosis. Despite those barriers, 90% trusted their care teams. Among respondents who had not undergone full bladder removal, 93% strongly or somewhat agreed they would try anything to avoid it. The survey's unweighted results represent only the individuals surveyed, not the wider military or veteran population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) will participate in two investor conferences in London on November 16, 2026, during London Life Sciences Week.

Senior leadership will discuss clinical and commercial priorities. The UBS Global Biopharma Conference presentation runs from 10:40–11:10 GMT; the Jefferies Global Healthcare Conference fireside chat with research analyst Roger Song follows at 12:00–12:25 GMT. The company plans to discuss its QUILT-2.005 bladder cancer study findings and work to expand global access to ANKTIVA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) reported third-quarter 2026 net product revenue of $48.7 million alongside expanded ANKTIVA approval and international commercialization.

Product revenue rose 53% year over year; nine-month revenue increased 92% to $143.6 million. Third-quarter net loss attributable to common stockholders widened to $184.6 million from $67.3 million. Cash, cash equivalents and marketable securities totaled $334.3 million at September 30.

On October 14, the FDA expanded ANKTIVA plus BCG approval to include high-grade papillary-only bladder tumors unresponsive to BCG. A trial in patients not previously treated with BCG met its primary endpoint; ImmunityBio plans a supplemental application in Q4 2026. Israel approved the combination, and European commercial treatment began in early Q4. ANKTIVA is approved or authorized in 35 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.66%
Tags
Rhea-AI Summary

ImmunityBio (IBRX) and Rafa Laboratories announced Israeli Ministry of Health approval of ANKTIVA plus BCG for adults with BCG-unresponsive bladder cancer.

The Israeli indication covers non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors—cancer confined to the bladder lining that has not responded to BCG treatment. Approval came four months after submission through an accelerated review pathway. The companies expect the registration license within the coming weeks.

Under their distribution agreement, Rafa is the exclusive commercialization partner in Israel. ANKTIVA is now authorized in 35 countries. The Israeli indication differs from the expanded U.S. label, which also includes adults with papillary-only disease. U.S. safety information warns that delaying bladder-removal surgery can lead to muscle-invasive or metastatic bladder cancer, which can be lethal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.66%
Tags
none
-
Rhea-AI Summary

ImmunityBio (IBRX) announced that ANKTIVA plus BCG met the primary efficacy endpoint in the randomized QUILT-2.005 bladder cancer trial. The final analysis of Cohort A showed a statistically significant efficacy improvement versus BCG alone in BCG-naïve patients with carcinoma in situ, with or without papillary tumors. BCG-naïve means receiving BCG-based therapy for the first time. The trial enrolled 370 randomized patients with high-grade non-muscle invasive bladder cancer, disease that has not invaded the bladder muscle.

The most common treatment-emergent and treatment-related adverse events were consistent with BCG alone; no treatment-related deaths were reported. Patient-reported quality of life was maintained, and median response duration had not yet been reached. ImmunityBio expects to submit a supplemental approval application to the FDA by year-end 2026. Additional study details will be presented at an upcoming medical congress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.66%
Tags
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) announced that the first European patients received ANKTIVA plus BCG for bladder cancer in Germany and Austria.

The treatment covers adults with non-muscle invasive bladder cancer that has not responded to BCG, with carcinoma in situ, with or without papillary tumors. The European Commission granted conditional marketing authorization in February 2026, covering all 27 EU member states plus Iceland, Norway and Liechtenstein.

Accord Healthcare provides commercial and market access support, while Uniphar supports distribution and supply. ImmunityBio retains all global rights to ANKTIVA and is working with its partners to expand European access. The authorization requires additional long-term safety and efficacy data and annual renewal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.72%
Tags
none
Rhea-AI Summary

ImmunityBio (IBRX) completed database lock for its registrational trial testing ANKTIVA plus BCG in patients receiving BCG-based bladder cancer therapy for the first time. Cohort A of QUILT-2.005 randomized 366 patients with non-muscle invasive bladder cancer to the combination or BCG alone. The chemotherapy-free combination is delivered directly into the bladder. Database lock followed data review, verification and reconciliation, enabling final analysis.

The trial tests whether adding ANKTIVA improves complete response rates. An FDA-requested interim analysis showed statistically significantly longer complete response duration with the combination versus BCG alone. Final analysis of the primary and secondary endpoints is underway. ImmunityBio expects topline results in November 2026 and remains on track for a supplemental approval application in fourth-quarter 2026 to potentially expand ANKTIVA’s indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
Rhea-AI Summary

ImmunityBio (IBRX) published long-term Phase 2/3 results showing a 71% complete response rate with ANKTIVA plus BCG in bladder cancer. The QUILT-3.032 analysis in the Journal of Urology included 100 patients with BCG-unresponsive non-muscle invasive bladder cancer and carcinoma in situ, with or without papillary disease. Complete response means no detectable cancer.

Median complete-response duration was 26.6 months, with responses extending beyond 53 months. Among responders, cystectomy-free survival—survival without bladder removal—was 84% at 36 months; 4% progressed to muscle-invasive disease. Three-year disease-specific survival was 98.2%, and progression-free survival was 80.9%. Grade 3 treatment-related adverse events occurred in 4% of patients; none were Grade 4 or 5. Separately, the FDA expanded ANKTIVA’s approved indication in October 2026 to include BCG-unresponsive papillary-only disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.20%
Tags
-
Rhea-AI Summary

ImmunityBio (IBRX) received expanded FDA approval for ANKTIVA plus BCG to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer, including papillary-only tumors. BCG is a bladder cancer immunotherapy; BCG-unresponsive disease no longer responds to it. The expanded indication adds papillary-only disease to the April 2024 approval for carcinoma in situ (CIS), with or without papillary tumors.

The FDA reviewed available scientific information, including previously demonstrated efficacy in patients with CIS, with or without papillary tumors. In QUILT-3.032 Cohort A, 62% of 77 patients achieved a complete response (95% confidence interval: 51%–73%). Among responders, 58% maintained a response for at least 12 months and 40% for at least 24 months. Most treatment-related adverse events were grade 1 to 2. The prescribing information warns that delaying bladder-removal surgery can lead to potentially lethal metastatic bladder cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) will participate in a virtual fireside chat at the Piper Sandler Virtual Oncology Symposium on October 16, 2026.

Founder, Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong will join moderator Ted Tenthoff, Piper Sandler’s Managing Director and Senior Research Analyst. The session runs from 1:00–1:25 p.m. ET, during the symposium taking place October 15–16, 2026. Piper Sandler is the contact for attendance information and access to session recordings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none

FAQ

What is the current stock price of ImmunityBio (IBRX)?

ImmunityBio (IBRX) last closed at $6.70.

What is the market cap of ImmunityBio (IBRX)?

The market cap of ImmunityBio (IBRX) is approximately $7.1B.